What to know about the new EPA rule limiting'forever chemicals' in tap water
Wednesday the Environmental Protection Agency announced new drinking water standards to limit people's exposure to some PFAS chemicals. For decades, PFAS have been used to waterproof and stain-proof a variety of consumer products. These "forever chemicals" in a host of products — everything from raincoats and the Teflon of nonstick pans to makeup to furniture and firefighting foam. Because PFAS take a very long time to break down, they can accumulate in humans and the environment. Now, a growing body of research is linking them to human health problems like serious illness, some cancers, lower fertility and liver damage....
Source: NPR Health and Science - April 12, 2024 Category: Consumer Health News Authors: Pien Huang Source Type: news
Texas Surgeon Is Accused of Secretly Denying Liver Transplants
A Houston hospital is investigating whether a doctor altered a transplant list to make his patients ineligible for care. A disproportionate number of them have died while waiting for new organs. (Source: NYT Health)
Source: NYT Health - April 11, 2024 Category: Consumer Health News Authors: Brian M. Rosenthal and Jessica Silver-Greenberg Tags: Kidneys Liver Doctors Transplants Hospitals Memorial Hermann Houston (Tex) Texas United States Source Type: news
Midlife Deaths of Despair Increased From 1999 to 2022
THURSDAY, April 11, 2024 -- Midlife deaths from suicide, drug overdose, and alcoholic liver disease, collectively known as deaths of despair, increased from 1999 through 2022, according to a research letter published online April 10 in JAMA... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 11, 2024 Category: Pharmaceuticals Source Type: news
Cochrane International Mobility - Yu-Tian Xiao
Cochrane ' s members and supporters come from more than 130 countries, worldwide. Our volunteers and contributors are researchers, health professionals, patients, carers, people passionate about improving health outcomes for everyone, everywhere.Getting involved in Cochrane ’s work means becoming part of a global community.The Cochrane International Mobility programmeconnects successful applicants with a placement in a host Cochrane Group, where they learn about the production, use, and knowledge translation of Cochrane reviews. The prgramme offers opportunities for learning and training not only for participants but als...
Source: Cochrane News and Events - April 11, 2024 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Metabolite in Red Meat Increases Kidney Disease Risk Metabolite in Red Meat Increases Kidney Disease Risk
Trimethylamine N-oxide could be a novel risk factor and intervention target for chronic kidney disease.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 11, 2024 Category: Consumer Health News Tags: Nephrology Clinical Summary Source Type: news
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune Why Alpine Immune Sciences Stock …
On Wednesday, Vertex Pharmaceuticals Incorporated VRTX agreed to acquire Alpine Immune Sciences Inc ALPN for $65 per share or approximately $4.9 billion in cash. Alpine’s lead molecule, povetacicept (ALPN-303), is a highly potent and effective dual antagonist of BAFF (B cell activating factor) and…#baff #phase2 #phase3 #vertex #proteinuria #hematuria #alpine #alpn (Source: Reuters: Health)
Source: Reuters: Health - April 11, 2024 Category: Consumer Health News Source Type: news
Boston company to buy Alpine Immune Sciences for $4.9B
The Seattle biotech is developing a drug to treat kidney disease. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 11, 2024 Category: Biotechnology Authors: Don Seiffert Source Type: news
CEUS adds to locoregional therapy for liver disease
Contrast-enhanced ultrasound (CEUS) can improve locoregional therapy for treating metastatic disease of the liver, according to early study results presented April 10 at UltraCon.
In her presentation, PhD candidate Corinne Wessner from Thomas Jefferson University in Philadelphia, PA, highlighted initial findings from her team’s ongoing work suggesting that microbubble destruction from CEUS triggering is safe and well-tolerated among patients with intrahepatic cholangiocarcinoma (ICC) and metastatic liver disease who also receive transarterial radioembolization with yttrium-90 (Y90-TARE).
“When we add the ultrasound-t...
Source: AuntMinnie.com Headlines - April 11, 2024 Category: Radiology Authors: Amerigo Allegretto Tags: Ultrasound Source Type: news
Study Assuages Thyroid Cancer Fears With GLP-1 Receptor Agonists
(MedPage Today) -- A Scandinavian cohort study suggested a popular class of diabetes drug did not put patients at an elevated risk for thyroid cancer, a longtime lingering concern with this drug class.
Compared with DPP-4 inhibitors, patients... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 10, 2024 Category: Urology & Nephrology Source Type: news
Vertex to acquire Seattle biotech for $4.9B
Vertex Pharmaceuticals Inc. has agreed to buy a Seattle-based biotech developing a drug to treat kidney disease for $4.9 billion, the biggest acquisition in the Boston company ’s history. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - April 10, 2024 Category: Pharmaceuticals Authors: Don Seiffert Source Type: news
Vertex to Buy Kidney Disease Drug Developer for $4.9 Billion
(Source: Reuters: Health)
Source: Reuters: Health - April 10, 2024 Category: Consumer Health News Source Type: news
Vertex Pharmaceuticals to Acquire Alpine Immune Sciences for $4.9 Billion
Transaction would give the pharmaceutical giant access to Alpine’s potential treatment for chronic kidney disease. (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2024 Category: Consumer Health News Source Type: news
Managing CKD in Primary Care: Latest Guidelines Managing CKD in Primary Care: Latest Guidelines
An explosion of new treatments can stave off the need for dialysis in many patients with CKD.Medscape Family Medicine (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 10, 2024 Category: Consumer Health News Tags: Nephrology Commentary Source Type: news
Black and Native Americans Hit Hardest by'Deaths of Despair '
WEDNESDAY, April 10, 2024 -- More middle-aged Black and Native Americans are now falling prey to“deaths of despair” than whites, a new study finds.
These deaths -- from suicide, drug overdose and alcoholic liver disease -- initially... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 10, 2024 Category: General Medicine Source Type: news
No Difference in Kidney Failure Risk Between Three Anti-VEGF Agents for Eye Disease
(MedPage Today) -- Of three anti-vascular endothelial growth factor (VEGF) drugs used to treat several serious eye diseases, there was no substantially different relative risk for kidney failure, a retrospective cohort study suggested.
Among over... (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - April 10, 2024 Category: Urology & Nephrology Source Type: news
